PDCD1 and neoplasm: While blocking the interaction between PD-1 and its ligands [PD-L1 and programmed cell death ligand 2 (PD-L2)], pembrolizumab facilitates the recognition of tumor antigens by tumor-specific T cells, thereby promoting their effector functions to eliminate tumor cells (33).